[PR]まずは試したいあなたに。トライアルサイズも特別価格 >>『PRIME BUY抗体特割キャンペーン(4/21~)

ITM2C Polyclonal antibody, PBS Only

ITM2C Polyclonal Antibody for IHC, Indirect ELISA
Cat No. 13601-1-PBS

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

IHC, Indirect ELISA

Formulation:  PBS Only
PBS and Azide
PBS Only
Conjugate:  Unconjugated
Size/Concentration: 

-/ -


ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。


国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター(国内)に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。


保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換/補填対応を承ります。詳細はこちらをご覧ください。


Tested Applications

Recommended dilution

ApplicationDilution
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Product Information

13601-1-PBS targets ITM2C in IHC, Indirect ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen ITM2C fusion protein Ag3876 相同性解析による交差性が予測される生物種
Full Name integral membrane protein 2C
Calculated molecular weight230aa,26 kDa; 267aa,30 kDa
Observed molecular weight 30 kDa
GenBank accession numberBC025742
Gene Symbol ITM2C
Gene ID (NCBI) 81618
RRIDAB_2877960
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
UNIPROT IDQ9NQX7
Storage Buffer PBS only , pH 7.3
Storage ConditionsStore at -80°C.

Background Information

The Integral membrane protein 2C (ITM2C) is a type II integral transmembrane protein belonging to a family composed of at least two other members, ITM2A and ITM2B. ITM2C, often called transmembrane protein BRI3, is highly expressed in brain tissue. Yeast two-hybrid screen system revealed that BRI3 could interact with beta-secretase beta-amyloid protein converting enzyme (BACE)1 and the microtubule-destabilizing protein SCG10 (STMN2). It may play a role in TNF-induced cell death and neuronal differentiation. BRI3 was found to inhibit the various processing of amyloid precursor protein (APP) by blocking the access of alpha- and beta-secretases to APP, competitive inhibition of APP processing by BRI3 may provide a new approach to Alzheimer disease (AD) therapy and prevention.

Loading...